Single tipifarnib and cyclosporin A treatments of three primary AML cells showed a very close correspondence between modulation by tipifarnib and cyclosporin A, (Figure5b), indicating similar potency between the two agents in inhibiting Pgp activity. This evidence concerns the gene PGP and acute myeloid leukemia.